Phosphodiesterase 2A inhibition corrects the aberrant behavioral traits observed in genetic and environmental preclinical models of Autism Spectrum Disorder

Pharmacological inhibition of phosphodiesterase 2A (PDE2A), which catalyzes the hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), has recently been proposed as a novel therapeutic tool for Fragile X Syndrome (FXS), the leading monogenic cause of Autism Sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiavi, Sara, Carbone, Emilia, Melancia, Francesca, di Masi, Alessandra, Jarjat, Marielle, Brau, Fréderic, Cardarelli, Silvia, Giorgi, Mauro, Bardoni, Barbara, Trezza, Viviana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956682/
https://www.ncbi.nlm.nih.gov/pubmed/35338117
http://dx.doi.org/10.1038/s41398-022-01885-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956682/
https://www.ncbi.nlm.nih.gov/pubmed/35338117
http://dx.doi.org/10.1038/s41398-022-01885-2

Ejemplares similares